Boston Scientific Corporation (BSX)

NYSE · Marlborough, Massachusetts, USA · Founded 1979 · CEO Michael Mahoney

Valuation summary

$41.43 fair value versus $42.99 in the market, a difference of -3.6%. Rated Hold.

Fair value per share$41.43
Current share price$42.99
Upside / downside-3.6%
Bear case$22.96
Bull case$69.04
Discount rate (WACC)8.4%
Terminal growth2.70%
Market capitalisation$62B
EV / Sales3.5x

About Boston Scientific Corporation

Founded in 1979 by John Abele and Peter Nicholas to commercialise less-invasive medical devices. Michael Mahoney has been CEO since 2012 and has overseen one of the strongest turnarounds in the sector. Boston Scientific makes cardiovascular devices, endoscopy equipment and urology products. Its Farapulse pulsed field ablation system, used to treat atrial fibrillation, has been the fastest device launch in the company's history.

Investment case

  • Farapulse remains a leading pulsed field ablation system, and international electrophysiology sales grew 23% in the second quarter of 2026.
  • A restructuring programme targeting roughly $500 million of run-rate savings gives management a lever on margins while growth slows.
  • Well-executed acquisition strategy that has repeatedly bought growth at reasonable prices.

Key risks

  • Medtronic, Johnson & Johnson and Abbott are taking US pulsed field ablation share, and US electrophysiology sales grew only 3% in the second quarter of 2026.
  • Watchman demand has slowed sharply, with US stand-alone procedures down in the low teens in the second quarter of 2026 after new stroke-risk evidence reduced referrals.
  • An August 2026 cyberattack cut third-quarter growth by about 3 points and EPS by $0.07, and management expects 2027 sales and EPS to be hard to grow.

Recent developments

Revenue by segment

Cardiovascular63%
MedSurg37%

Five-year forecast

RevenueFree cash flow
Year 1$22.9B$2.6B
Year 2$24.9B$3.0B
Year 3$27.1B$3.3B
Year 4$29.6B$3.7B
Year 5$32.2B$4.2B

What the street says

Sentiment has reversed sharply: the shares lost more than half their value between late December 2025 and September 2026 as US electrophysiology share losses and a Watchman slowdown forced repeated guidance cuts. The third quarter of 2026 confirmed the damage, with organic growth of 1.5%, fourth-quarter organic sales guided down 1-3% and management warning it will be challenged to grow sales and EPS in 2027 before a return to growth in 2028.

Comparable companies: IQV · GEHC · MDLN · MDT · SYK · SNY · A · TEVA

Open the interactive model, price chart and sensitivity grid →